KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 144 filers reported holding KARYOPHARM THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 1.33 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $20,740 | +74.1% | 13,735 | 0.0% | 0.00% | – |
Q4 2023 | $11,916 | -35.3% | 13,735 | 0.0% | 0.00% | – |
Q3 2023 | $18,405 | -89.0% | 13,735 | -85.3% | 0.00% | – |
Q2 2023 | $166,970 | -11.5% | 93,279 | +92.3% | 0.00% | – |
Q1 2023 | $188,602 | +20.9% | 48,511 | +5.9% | 0.00% | – |
Q4 2022 | $156,004 | -24.6% | 45,819 | +21.2% | 0.00% | – |
Q3 2022 | $207,000 | +37.1% | 37,819 | +12.6% | 0.00% | – |
Q2 2022 | $151,000 | -35.5% | 33,575 | +5.4% | 0.00% | – |
Q1 2022 | $234,000 | +14.1% | 31,845 | 0.0% | 0.00% | – |
Q4 2021 | $205,000 | +17.1% | 31,845 | +6.0% | 0.00% | – |
Q3 2021 | $175,000 | -7.9% | 30,049 | +63.9% | 0.00% | – |
Q2 2021 | $190,000 | -5.9% | 18,334 | -4.3% | 0.00% | – |
Q1 2021 | $202,000 | -31.3% | 19,163 | +0.9% | 0.00% | – |
Q4 2020 | $294,000 | +5.4% | 18,993 | -0.6% | 0.00% | – |
Q3 2020 | $279,000 | -33.6% | 19,111 | -13.9% | 0.00% | – |
Q2 2020 | $420,000 | +65.4% | 22,191 | +67.9% | 0.00% | – |
Q1 2020 | $254,000 | -17.0% | 13,219 | -17.4% | 0.00% | – |
Q4 2019 | $306,000 | +139.1% | 16,009 | +20.7% | 0.00% | – |
Q3 2019 | $128,000 | +80.3% | 13,265 | +11.9% | 0.00% | – |
Q2 2019 | $71,000 | +20.3% | 11,854 | +17.2% | 0.00% | – |
Q1 2019 | $59,000 | -37.9% | 10,116 | 0.0% | 0.00% | – |
Q4 2018 | $95,000 | -27.5% | 10,116 | +31.3% | 0.00% | – |
Q3 2018 | $131,000 | 0.0% | 7,705 | 0.0% | 0.00% | – |
Q2 2018 | $131,000 | +52.3% | 7,705 | +20.1% | 0.00% | – |
Q1 2018 | $86,000 | -4.4% | 6,413 | -31.2% | 0.00% | – |
Q4 2017 | $90,000 | -11.8% | 9,318 | 0.0% | 0.00% | – |
Q3 2017 | $102,000 | +39.7% | 9,318 | +16.5% | 0.00% | – |
Q2 2017 | $73,000 | -17.0% | 8,000 | +17.5% | 0.00% | – |
Q1 2017 | $88,000 | +25.7% | 6,809 | -8.8% | 0.00% | – |
Q4 2016 | $70,000 | +62.8% | 7,463 | +67.8% | 0.00% | – |
Q3 2016 | $43,000 | +38.7% | 4,448 | 0.0% | 0.00% | – |
Q2 2016 | $31,000 | +47.6% | 4,448 | +81.7% | 0.00% | – |
Q1 2016 | $21,000 | -36.4% | 2,448 | 0.0% | 0.00% | – |
Q4 2015 | $33,000 | +26.9% | 2,448 | 0.0% | 0.00% | – |
Q3 2015 | $26,000 | -58.7% | 2,448 | 0.0% | 0.00% | – |
Q2 2015 | $63,000 | -16.0% | 2,448 | 0.0% | 0.00% | – |
Q1 2015 | $75,000 | -16.7% | 2,448 | 0.0% | 0.00% | – |
Q4 2014 | $90,000 | 0.0% | 2,448 | 0.0% | 0.00% | – |
Q3 2014 | $90,000 | – | 2,448 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Delphi Management Partners VIII, L.L.C. | 2,263,006 | $13,170,000 | 9.51% |
Palo Alto Investors LP | 5,383,052 | $31,329,000 | 1.89% |
Birchview Capital, LP | 246,000 | $1,432,000 | 0.97% |
Lombard Odier Asset Management (Switzerland) SA | 1,517,804 | $8,834,000 | 0.55% |
Rubric Capital Management LP | 3,375,758 | $19,647,000 | 0.55% |
RICE HALL JAMES & ASSOCIATES, LLC | 1,401,861 | $8,159,000 | 0.30% |
AlphaCentric Advisors LLC | 136,000 | $792,000 | 0.20% |
Bridgefront Capital, LLC | 20,946 | $122,000 | 0.13% |
Hennion & Walsh Asset Management, Inc. | 407,474 | $2,371,000 | 0.12% |
Virtus ETF Advisers LLC | 44,364 | $258,000 | 0.11% |